Related by context. All words. (Click for frequent words.) 84 statistically significant p 75 P ≤ 74 statistical significance p 73 placebo p = 71 placebo p 71 achieved statistical significance 70 mg p = 70 % CI #.#-#.# [001] 69 Xalatan R 69 μmol L 69 mmHg p = 69 lumbar spine BMD 68 P = .# 67 Doxil ® 67 mg kg Hematide 67 #.#/#.# mmHg [001] 67 QTcF 67 achieved ACR# 67 % Confidence Interval 67 locoregional recurrence 66 methotrexate monotherapy 66 morphometric vertebral fractures 66 IOP lowering 66 p = .# [002] 66 % CI #.#-#.# [003] 66 CI -#.# 66 mL/min/#.# m 2 66 statistical significance p = 66 tirofiban 65 oxycodone CR 65 MADRS score 65 tipranavir r 65 postintervention 65 recurrent glioblastoma multiforme 65 noninferiority 65 confidence interval #.#-#.# 65 lispro 65 periprocedural 65 leukocyte count 65 titrated glipizide 65 p ≤ 65 confidence interval CI 65 serum estradiol 64 ximelagatran 64 statistically significant 64 nondiabetic patients 64 genotypic resistance 64 pCR 64 serum urate 64 PSA nadir 64 CC genotype 64 tolterodine ER 64 cilostazol 64 Hazard Ratio = 64 CCyR 64 interobserver reliability 64 Hazard Ratio 63 binary restenosis 63 intact parathyroid hormone 63 comparator arm 63 HIV RNA 63 patients undergoing CABG 63 nonsignificant 63 clodronate 63 intima media thickness 63 HOMA IR 63 complete cytogenetic response 63 pmol L 63 HbA 1c 63 linaclotide treated 63 attain statistical significance 63 T2 lesion volume 63 median PFS 63 sUA 63 reinfarction 63 posttreatment 63 creatinine ratio 63 5-FU/LV 63 baseline LDH 63 mg kg dose 63 Hazard Ratio HR 63 noninferior 63 -#.# ± [002] 63 mcg QD 63 definite stent thrombosis 63 KRAS mutations occur 63 FOLFOX4 63 ritonavir boosted 63 undetectable HBV DNA 63 certolizumab 63 APTIVUS r 63 viral kinetics 63 albumin excretion rate 63 cinacalcet 63 thyroglobulin 63 p = #.# [003] 63 p = NS 63 Subgroup analysis 63 HBeAg seroconversion 63 colorectal adenoma 63 Aptivus ® 63 HbA 1c levels 63 pg mL 62 #mg BID [001] 62 dalteparin 62 Stent thrombosis 62 FDG uptake 62 annualized relapse 62 MMSE score 62 biochemical relapse 62 octreotide LAR 62 ropivacaine 62 serum TSH 62 ACR# response 62 carotid IMT 62 sirolimus stent 62 β blockers 62 multivariable adjusted 62 LVEF 62 infliximab monotherapy 62 HDRS 62 prospectively defined 62 mg QD 62 intracoronary 62 p = 62 Ishak fibrosis score 62 idraparinux 62 eplerenone 62 NEVO ™ 62 Kaplan Meier analysis 62 PRADAXA #mg 62 methacholine challenge 62 ejection fractions 62 alteplase 62 multivariable analysis 62 serum urate levels 62 baseline HbA1c 62 log# copies mL 62 lamivudine refractory patients 62 timolol 62 LEXIVA r 62 recurrent venous thromboembolism 62 troponin T 62 response CCyR 62 DAS# remission 62 log# IU mL 62 Thal Dex 62 posttransplant 62 atorvastatin #mg 62 NNRTI resistance 62 intravenous dosing 62 Crohn Disease Activity 62 interobserver agreement 62 ADAS Cog 62 paclitaxel eluting stents 62 serum phosphate 62 XIENCE V PROMUS Stent 62 lopinavir r 62 CsA 62 unfractionated heparin 62 plasma pharmacokinetics 61 EpCAM expression 61 clinically meaningful improvement 61 chlorambucil 61 serum BDNF 61 doxorubicin docetaxel 61 neurologic progression 61 IFN α 61 stent binary restenosis 61 nicardipine 61 aspirin clopidogrel 61 mg/m2 dose 61 μg kg 61 pegylated liposomal doxorubicin 61 antiretroviral naïve 61 abacavir lamivudine 61 mmol l 61 intraobserver 61 #mg dose [002] 61 HBeAg 61 NATRECOR R 61 interquartile range 61 ADAS cog 61 antibody titer 61 urate lowering therapy 61 advanced adenomas 61 mg ustekinumab 61 platelet reactivity 61 tumor histology 61 DAS# CRP 61 mmHg diastolic 61 highly emetogenic 61 NMIBC 61 rt PA 61 μg L 61 bladder carcinoma 61 #.#/#.# mm Hg [003] 61 fluticasone salmeterol 61 univariate analysis 61 relapsed MM 61 dapagliflozin plus 61 somatostatin analog 61 prespecified 61 locoregional disease 61 micafungin 61 sustained virological response 61 p = #.# [002] 61 adenoma recurrence 61 CI #.#-#.# p = 61 dosing cohort 61 nadroparin 61 μg mL 61 nonsignificant difference 61 plus dexamethasone 61 IFN alfa 61 nonrandomized 61 NIHSS 61 HBeAg negative patients 61 nadolol 61 CR nPR 61 kappa = 61 bivalirudin monotherapy 61 cisplatin vinorelbine 61 reach statistical significance 61 #mg BID [003] 61 preoperative chemotherapy 61 FOLFIRI 61 splenectomized 61 ovarian carcinoma 61 ertapenem 61 nmol 61 mcg BID 61 ibandronate 61 zoledronate 61 lactate dehydrogenase LDH 61 MGd 61 MBq 61 caspofungin 61 virological response 61 corrected QT interval 60 oral allopurinol 60 mg TID 60 mITT population 60 TAXUS p value 60 PASI scores 60 CI #.#-#.# [002] 60 favorable pharmacokinetic profile 60 virological failure 60 TMC# r 60 virologic 60 intravesical therapy 60 HbA1C levels 60 teriparatide 60 underwent resection 60 clinicopathological 60 advanced adenoma 60 AUA Symptom Score 60 mmol kg 60 #Gy 60 HAQ DI 60 ARB telmisartan 60 estramustine 60 biochemical recurrence 60 liver histology 60 radiotherapy RT 60 CIMZIA ™ 60 tenecteplase 60 chemoradiotherapy 60 CTEPH 60 mcg albinterferon alfa 2b 60 % CI #.#-#.# [006] 60 HbA1C 60 IFN beta 60 p = #.# [004] 60 FOLPI 60 ExTRACT TIMI 60 tHcy 60 microbiological eradication 60 TIMP 1 60 seliciclib 60 postprocedure 60 plus methotrexate 60 mitoxantrone 60 ischemic cardiomyopathy 60 mcg kg 60 neutrophil counts 60 FOLFOX6 60 dopamine partial agonist 60 LV dysfunction 60 achieved CCyR 60 r2 = 60 ATACAND 60 experienced virologic failure 60 serum phosphorous 60 plasminogen activator inhibitor 60 desvenlafaxine succinate 60 elevated troponin 60 urinary N telopeptide 60 STRIDE PD 60 CI = 60 mutated KRAS 60 bosentan 60 multivariate Cox 60 NYHA functional class 60 log# 60 paricalcitol 60 clevidipine 60 % CI #.#-#.# [007] 60 4mg/kg 60 pegylated interferon alfa 2b 60 mcg dose 60 PEG IFN 60 latanoprost 60 apolipoprotein B 60 posaconazole 60 nmol liter 60 thyrotropin levels 60 ruboxistaurin 60 unfractionated heparin UFH 60 pT3 60 mg/# hours 60 coinfected patients 60 ketorolac 60 haematologic 60 univariate 60 XIENCE V demonstrated 60 generation antisense inhibitor 60 hsCRP levels 60 nonfatal MI 60 TPV r 60 NPH insulin 60 nmol L 60 echocardiographic parameters 60 oral Hycamtin 60 lopinavir r arm 60 x ULN 60 lanthanum carbonate 60 CR CRu 60 EDSS score 60 bendamustine 60 CIMZIA TM 60 timepoints 60 chemoradiation therapy 60 completely resected 60 serum magnesium 60 progression TTP 60 dose proportionality 60 Subgroup analyzes 60 HGPIN 60 CYPHER Stent 60 resected pancreatic cancer 60 serum HBV DNA 60 endometrial thickness 60 tacrolimus ointment 60 tiotropium 60 pegaptanib 60 transaminase elevations 60 postoperative complication 60 glycosylated hemoglobin HbA1c 60 prostatic adenocarcinoma 60 Ki# 60 femoral neck fracture 60 seroprotection 60 adriamycin 60 WOMAC scores 60 pharmacodynamic PD 60 mCi 60 PSADT 60 NIHSS score 60 Pyratine XR TM 60 NNT = 60 PaO 2 60 prospectively randomized 60 -#.# mg dL [002] 60 neostigmine 60 mg dose 60 FluCAM 60 CIMZIA TM certolizumab pegol 60 glycated hemoglobin HbA1c 60 % CI #.#-#.# [008] 60 -#.# mg dL [001] 60 inotropic agents 60 underwent surgical resection 60 intravenous cyclophosphamide 60 atazanavir ritonavir 60 tipranavir ritonavir 60 tapentadol ER 60 hip BMD 60 8mg/kg 60 cTnI 60 MACCE 60 serum ALT 60 HMG CoA reductase inhibitor 60 taxane resistant 60 HER2 expression 60 oxcarbazepine 60 abacavir Ziagen 59 target lesion revascularizations 59 mmHg p 59 bronchoalveolar lavage 59 Index CDAI 59 Pharmacodynamic 59 clinicopathological features 59 mcg Albuferon 59 composite endpoint 59 logistic regression analysis 59 everolimus eluting stents 59 postoperative mortality 59 Xelox 59 low dose Iluvien 59 prospectively stratified 59 irbesartan 59 recurrent VTE 59 Taxus Stent 59 racemic albuterol 59 chlorthalidone 59 plasma leptin 59 symptomatic VTE 59 decitabine 59 serum cortisol 59 logMAR 59 salmeterol fluticasone propionate 59 hemoglobin Hb 59 #mg QD [001] 59 invasive carcinomas 59 ancrod 59 HRCT 59 normotensive 59 mg BID dose 59 zotarolimus eluting stent 59 statistically significant predictor 59 pentoxifylline 59 timepoint 59 postop 59 F FDG PET 59 prespecified secondary 59 achieved sustained virological 59 electrophysiologic 59 NLX P# 59 #.#mg/dL 59 #F FDG PET 59 #mg/day [002] 59 argatroban 59 mg XP# 59 ULORIC 59 histologic subtype 59 Pharmacokinetic 59 angiographic outcomes 59 NATRECOR ® 59 prostate carcinoma 59 ischemia driven 59 mcg ml 59 CANCIDAS 59 symptomatic intracranial 59 pT2 59 PANSS scores 59 oral anticoagulation 59 LV ejection fraction 59 INCB# [003] 59 sodium nitroprusside 59 solifenacin 59 ACEI ARB 59 HCV SPRINT 59 otamixaban 59 Natalizumab 59 BMS p = 59 mRNA expression 59 AST ALT 59 sirolimus eluting stent 59 AUC0 59 TURBT 59 liver metastasis 59 6MWD 59 hormone receptor negative 59 infarct size 59 virologic failure 59 candesartan cilexetil 59 virologic response 59 protein excretion 59 demonstrated clinically meaningful 59 LPV r 59 NIH CPSI 59 arterial thromboembolic events 59 clinically meaningful 59 SVR# 59 anti Xa 59 -#.# log# 59 myocardial necrosis 59 Folfox 59 isoproterenol 59 risedronate 59 piperacillin tazobactam 59 EGFR TKI 59 baseline Hb 59 oral rivaroxaban 59 androgen suppression 59 darunavir ritonavir 59 Postoperatively 59 prolonged QT interval 59 antiarrhythmic drug 59 Serum creatinine 59 lactate dehydrogenase 59 Ceplene/IL-2 59 lymph node metastasis 59 g cm 59 specific antigen PSA 59 MAGE A3 ASCI 59 Vancocin p = 59 confidence intervals CIs 59 tolvaptan 59 serum uric acid 59 interferon ribavirin 59 oral FTY# 59 pg ml 59 LMWH 59 taxane refractory 59 Pharmacokinetic parameters 59 oral levofloxacin 59 -#.# p = 59 ‰ ¥ 59 TIMP 59 anemia hemoglobin 59 Operative mortality 59 HbA1c levels 59 PCWP 59 T2 lesions 59 teriflunomide 59 Secondary endpoints included 59 lymphocyte count 59 IIIa inhibitor 59 lumbar spine bone 59 fosamprenavir 59 atheroma volume 59 bezafibrate 59 mutated K ras 59 glargine 59 insulin detemir 59 mg qd 59 azacitidine 59 elevated ALT 59 ug kg 59 tranylcypromine 59 TEAEs 59 overt nephropathy 59 GP IIb IIIa inhibitors 59 ipsilateral stroke 59 evaluating tivozanib 59 intravenous bisphosphonates 59 OPCAB 59 primary patency 59 PREZISTA ritonavir 59 μg ml 59 ug ml 59 idarubicin 59 seropositivity 59 alanine aminotransferase 59 nonresponders 59 metastatic malignant 59 saline placebo 59 ABVD 59 serum creatinine levels 59 serum concentrations 59 SUVmax 59 EURIDIS 59 MAL PDT 59 death reinfarction 59 mmol L 59 Hb A1C 59 mRCC 59 BPH Symptom Score 59 non valvular atrial 59 primary aldosteronism 59 left ventricular systolic 59 fondaparinux 59 plasma cortisol 59 macroalbuminuria 59 monophasic 59 tPSA 58 pimecrolimus cream 58 tertile 58 non squamous histology 58 flutamide 58 nonmetastatic 58 heavily pretreated 58 inotropic 58 Histologic 58 #mg doses [002] 58 colorectal carcinoma 58 DAPT 58 hyperphenylalaninemia HPA due 58 ACTEMRA TM 58 colesevelam HCl 58 systolic dysfunction 58 beta 1a 58 salmeterol fluticasone 58 -#.# log# copies mL 58 cabazitaxel 58 sorafenib Nexavar 58 pmol liter 58 transdermal estradiol 58 adjuvant cisplatin 58 taxane therapy 58 GPIIb IIIa inhibitors 58 gadobutrol 58 DOXIL 58 bosutinib 58 uM 58 statistically significant efficacy 58 Non inferiority 58 inhaled iloprost 58 mCi kg 58 histologic findings 58 strontium ranelate 58 pharmacologically active isomer 58 histologically confirmed 58 imatinib therapy 58 g dl 58 Taxol ® 58 p = ns 58 RLAI 58 creatinine clearance 58 standard chemotherapy regimen 58 #mg/day [001] 58 A1c levels 58 multivariate analyzes 58 pioglitazone 58 LT NS# 58 efavirenz EFV 58 RE LY ® 58 EDSS scores 58 DAS# scores 58 carotid intima media 58 Median PFS 58 inhibitor RG# 58 intravitreal injections 58 Stent p = 58 Free Survival PFS 58 evaluable 58 Elitek 58 interobserver 58 CombAT 58 alanine aminotransferase ALT 58 fluoropyrimidine 58 symptom exacerbation 58 ARCOXIA 58 iodixanol 58 serum aminotransferase levels 58 μg dose 58 preintervention 58 clinically meaningful differences 58 mg d 58 IV bisphosphonates 58 ANOVA 58 glycated hemoglobin levels 58 antiangiogenic therapy 58 ADCS CGIC 58 HIV HCV coinfected 58 #.#ng/ml 58 carotid bruit 58 hemodynamic variables 58 ABCB1 58 abciximab 58 oblimersen 58 heterozygotes 58 ezetimibe simvastatin 58 GRN# 58 neutropenic sepsis 58 non splenectomized 58 antiarrhythmic 58 subtrochanteric 58 APPRAISE 58 rimonabant #mg 58 budesonide pMDI 58 antihypertensive therapy 58 dose clopidogrel 58 mitoxantrone plus 58 Virologic 58 Cmax 58 cardiac repolarization 58 TLUS 58 TNF blocker therapy 58 sargramostim 58 Pegylated Liposomal Doxorubicin 58 mesalamine granules 58 Cystatin C 58 esophageal carcinoma 58 cerebral oxygenation 58 symptomatic intracranial hemorrhage 58 aldosterone antagonists 58 parkinsonian symptoms 58 lesional 58 epoetin alpha 58 null responder 58 active comparator 58 foveal thickness 58 Partial Response 58 median survivals 58 corticosteroid dose 58 microg 58 pamidronate 58 amisulpride 58 estimated GFR 58 glomerular filtration 58 trastuzumab Herceptin ® 58 % CI #.#-#.# [002] 58 subgroup analyzes 58 DFMO 58 pharmacodynamic parameters 58 Severity MSCS score 58 Flu Cy 58 left ventricular dysfunction 58 neoadjuvant chemotherapy 58 CYT# potent vascular disrupting 58 bronchodilation 58 visceral metastases 58 tenofovir emtricitabine 58 NYHA class 58 XELOX 58 REYATAZ r arm 58 uncorrected visual acuity 58 preoperative PSA 58 evaluable subjects 58 dose cytarabine 58 Lucentis monotherapy 58 mycophenolate mofetil 58 mEq L 58 radical nephrectomy 58 interferon beta therapy 58 tocilizumab 58 ribavirin RBV 58 nelfinavir 58 mucinous 58 Navelbine 58 virologic responses 58 serum phosphorus 58 cytogenetic abnormalities 58 liposomal amphotericin B 58 QD dosing 58 Pharmacokinetics PK 58 thromboembolic 58 endoscopic remission 58 Brief Psychiatric 58 bovine thrombin 58 ug mL 58 eosinophil count 58 postdose 58 hematological parameters 58 myocardial viability 58 GSK# [001] 58 treat NNT 58 Lenalidomide 58 rCBF 58 cardiovascular calcification 58 fosbretabulin 58 oxaliplatin Eloxatin 58 5FU 58 mm Stent 58 GnRH agonist 58 PREZISTA r 58 nab paclitaxel 58 sotalol 58 Tasigna prolongs 58 dose cohort 58 thromboembolism 58 mcg mL 58 hyperacute 58 Rating Scale BPRS 58 microvessel density 58 perioperative complications 58 ALA PDT 58 administered subcutaneously 58 K ras mutations 58 VAPRISOL 58 Rating Scale MADRS 58 Leydig cell 58 QTc 58 CIN2 + 58 Teriflunomide 58 Pemetrexed 58 Secondary endpoints include 58 ara C 58 stratifying patients 58 angiographic restenosis 58 pretest probability 58 SGRQ 58 inotropic therapy 58 odds ratios ORs 58 KRAS status 58 GOUT 58 elevated IOP 58 Retreatment 58 PREMPRO 58 laboratory abnormalities 58 anti leukemic 58 elevated LDH 58 platelet inhibitor 58 VFEND 58 histological subtype 58 AUCs 58 SCIg 58 CHOP chemotherapy 58 rotigotine 58 Plasma concentrations 58 localized renal 58 Pioglitazone 58 antioxidant supplementation 58 FFNS 58 daunorubicin 58 deep venous thromboses 58 sustained virologic response 58 dobutamine 58 hypoperfusion 58 intracranial hemorrhage ICH 58 ng dl 58 selective modulator 58 cis retinoic acid 58 mIU L 58 interleukin IL -6 58 daily subcutaneous injections 58 reteplase 57 statistically significant reduction 57 scintigraphic 57 plasma creatinine 57 placebo dexamethasone 57 plus MTX 57 VaD 57 UPDRS scores 57 Fulvestrant 57 pyridostigmine 57 mg tid 57 HBeAg positive patients 57 dose dependently 57 diuretic chlorthalidone 57 Kaplan Meier curves 57 Pegasys plus Copegus 57 q8h 57 mammographic density 57 graft occlusion 57 umol L 57 achieve statistical significance 57 postoperative AF 57 ticagrelor 57 conjugated equine estrogen 57 liposomal doxorubicin 57 adjuvant radiotherapy 57 imipenem 57 nonvertebral fractures 57 EDEMA3 trial 57 T2DM 57 cobiprostone 57 prolactin elevation 57 prucalopride 57 anterior uveitis 57 eszopiclone 57 periprocedural MI 57 recurrent DVT 57 biopsy Gleason 57 knee osteoarthritis OA 57 anterior temporal 57 BENICAR HCT 57 FDA defined valvulopathy 57 simvastatin ezetimibe 57 complete cytogenetic 57 mol L 57 radiochemotherapy 57 oncologic outcomes 57 Adjuvant chemotherapy 57 perioperative mortality 57 Primary endpoints 57 HCV genotype 57 TACE 57 TroVax ® 57 radiographic progression 57 avosentan 57 antiretroviral naive 57 rFSH 57 ACUITY trial 57 postmenopausal osteoporotic women 57 thromboembolic events 57 antiangiogenic agent 57 aminotransferase levels 57 multivariable adjustment 57 UGT#A# * 57 locoregional 57 elevated transaminases 57 VELCADE melphalan 57 carotid plaque 57 plasma renin activity 57 fluorouracil leucovorin 57 riociguat 57 dexmedetomidine 57 fluorouracil 57 preoperatively 57 df = 57 hemoglobin A1c levels 57 HORIZONS AMI trial 57 biphasic insulin aspart 57 lymphocytosis 57 serum homocysteine 57 neurodevelopmental impairment 57 Tarceva TM 57 QTc prolongation 57 CALGB # [002] 57 splenectomized patients 57 Baseline characteristics 57 squamous histology 57 leuprorelin 57 antithrombotic therapy 57 iloprost 57 nmol l 57 mcg doses 57 receptor blocker 57 carcinoembryonic antigen 57 Score TOS 57 APTIVUS R 57 carotid artery thickness 57 Vidaza azacitidine 57 ACE inhibitor ramipril 57 oral diclofenac 57 hour bronchodilation 57 Thrombolysis 57 urinary albumin 57 headache nasopharyngitis 57 euthyroid 57 PegIFN RBV 57 urodynamic 57 SGPT 57 RECIST Response Evaluation Criteria 57 antitumor effect 57 brivaracetam 57 osteopenic 57 #.# US#YT = 57 plasma uric acid 57 endothelin receptor 57 mg Proellex 57 retinal thickness 57 eptifibatide 57 UACR 57 paroxysmal AF 57 polytherapy 57 PLX STROKE targeting 57 stavudine d4T 57 mg administered orally 57 bleomycin 57 DAS# [002] 57 chemosensitivity 57 #.#-#.# p = 57 antithrombotics 57 hematopoietic cancers 57 serum leptin 57 BEACOPP 57 hypogonadal 57 ALB # 57 gemcitabine carboplatin 57 serum PSA 57 CYP#D# inhibitor 57 Scale cognitive subscale 57 CK MB 57 placebo fluoxetine 57 femoral neck BMD 57 sitaxsentan 57 nondiabetics 57 amprenavir 57 Montgomery Asberg Depression 57 ß blockers 57 aminotransferases 57 aspartate aminotransferase AST 57 spirometric 57 ALT elevation 57 trimethoprim sulfamethoxazole 57 ASCUS 57 log# reduction 57 ascending dose 57 adjunctive placebo 57 serum calcium 57 exhaled NO 57 β blocker 57 serum prostate 57 kilogram mg kg 57 zonisamide SR 57 KRAS mutation status 57 pain palliation 57 prilocaine 57 glycoprotein IIb IIIa inhibitor 57 TDF FTC 57 CINQUIL 57 vertebral fracture 57 mm Hg diastolic 57 oral antidiabetic medication 57 hemodynamically significant 57 relapsers 57 INVEGA ® 57 dose Iluvien 57 ELACYT 57 analgesic efficacy 57 partial remissions 57 plus prednisone prednisolone 57 indinavir 57 clinically meaningful reductions